The Urgent Need for Medicare Reimbursement for Home Infusion Antibiotics amidst a Pandemic

Amber C Streifel¹ and Monica K Sikka²

1. Department of Pharmacy, Oregon Health and Science University, Portland, Oregon

2. Department of Medicine, Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon

Author Contact Information:

Corresponding Author

Amber Streifel, PharmD

3181 SW Sam Jackson Park Road

Portland, OR 97239

streifel@ohsu.edu
Summary: Medicare does not reimburse for home infusion, which leaves OPAT patients to seek treatment in high-risk settings. We recommend policy change to allow for adequate social distancing during the COVID-19 pandemic and increased risk for severe illness in this population.
Abstract:

The Centers for Medicare and Medicaid Services should immediately update current policies to include reimbursement for Medicare patients receiving intravenous antibiotics at home. The majority of these patients are over the age of 65 and at increased risk for severe illness due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Requiring them to travel to an infusion center, stay in a skilled nursing facility or remain in the hospital longer than necessary to receive treatment results in avoidable risk of exposure amidst a pandemic. Current policy has significant implications for increased cost and harm to both these patients and the US healthcare system.

Keywords: OPAT; COVID-19; Health Insurance Policy, CMS
Outpatient parenteral antimicrobial therapy (OPAT) is the administration of intravenous (IV) antibiotics in the outpatient setting. These settings include skilled nursing facilities (SNFs), infusion centers, hemodialysis centers, and the patient’s home. OPAT programs reduce costs and improve patient satisfaction by decreasing hospital length of stay for patients with severe infections requiring long courses of antibiotics.¹ Despite the established benefits of OPAT, care coordination for this service has historically been complex due to costs of antimicrobials in the United States and variable coverage among different health insurance providers. The COVID-19 pandemic has amplified these challenges given the urgent need for social distancing to protect patients from unnecessary exposure. Moreover, discharge to SNFs and long-term care facilities poses an even greater risk due to rapid spread of infections in these settings. Multiple outbreaks of COVID-19 in SNFs have already been reported.²⁻⁴ Though the majority of private insurance companies and most state Medicaid programs cover home infusion, there is a gap in Medicare coverage.⁵ Home infusion for Medicare patients leads to high out-of-pocket costs, forcing these patients to continue therapy at a SNF or infusion center. This is concerning as the majority of Medicare patients are over 65 years-old and at increased risk for severe COVID-19 infection.⁶ The current pandemic highlights the importance of Medicare reform to include reimbursement for IV antibiotics via home infusion.

Home infusion is a safe and recommended practice for the elderly receiving OPAT.¹ Administration of antibiotics at home has been shown to be cost-effective with estimated costs being half that of completing antibiotics in the hospital.⁷ One study showed consistently lower costs associated with home infusion with savings between $1928-$2974 per treatment course.⁸ Not all patients requiring IV
antibiotics are capable of administering antibiotics at home, however. Patients or a family member must be able to infuse the antibiotics in a safe home environment. At our institution, the infectious diseases team assesses the patient’s ability to participate in home infusion, and nurse case managers finalize disposition based on insurance coverage.

To qualify for Medicare coverage, individuals must be over the age of 65, however, individuals diagnosed with end-stage renal disease requiring intermittent hemodialysis and people who have qualified for Social Security Disability Insurance for at least 24 months may also qualify for coverage. Currently, Medicare Part B does not reimburse intravenous antibiotics via home infusion. Patients who qualify for Medicare can opt to select a MedAdvantage plan (Medicare Part C) in place of Medicare Part A and B. MedAdvantage plans are provided by commercial insurers and may or may not cover home infusion services. The National Home Infusion Association has undertaken significant efforts to change this policy. The 21st Century Cures Act and the Bipartisan Budget Act of 2018 include provisions that allow reimbursement of home infusion services. Unfortunately, the Centers for Medicare and Medicaid Services (CMS) has issued policy that results in home infusion reimbursement only when medications are administered by a nurse in the patient’s home. Further, this only applies to medications previously covered by Medicare Part B, which does not include antibiotics. Even if a patient has Medicare Part D prescription coverage, which may reimburse a portion of the antibiotic cost, patients would still be responsible for all other costs associated with home infusion like pharmacy services, nursing care coordination, labs, and vascular access dressing changes. Medicare covers infusion of IV antibiotics at an infusion center as well as limited stays at a SNF, both of which are high risk settings for exposure to SARS-CoV-2. At the time this piece is being written there are active bills in the house and senate that could influence this CMS policy: The Preserving Patient Access to Home Infusion Act (S. 3457, sponsored by Senator Mark R Werner [D-VA] and H.R. 6218, sponsored by Representative Eliot L. Engel [D-NY]). While this legislation represents potential progress, these changes are needed urgently, especially as
the United States begins phased re-opening. Additionally, although work on a vaccine against SARS-CoV-2 is underway, it is unlikely we will have access to a vaccine for at least a year, necessitating protection of our older patents via social distancing whenever possible.9

We aimed to reduce unnecessary hospital days for prolonged IV antibiotic treatment for patients at our institution as spread of the virus and limited testing capacity made the hospital a likely place to acquire infection. Additionally, for patients without skilled needs being treated in SNFs, we actively changed antibiotic regimens to alternative agents, like oral antibiotics or long-acting agents to allow discharge home. Although antibiotic therapy at an outpatient infusion center may not be as high risk as inpatient stays at the hospital or a SNF, it still may mean increased costs to patients for transportation. These infusion centers often service immunocompromised hosts receiving chemotherapy or biologic agents, making effective social distancing even more integral for this setting.6 Reducing the number of patients presenting to healthcare settings such as infusion center waiting rooms is of increasing benefit given data that suggests that SARS-CoV-2 persists in aerosols and on certain surfaces.10

We evaluated outpatient settings for the 144 adults admitted to our OPAT program from October through December of 2019, prior to the first US case and the declaration by the World Health Organization of SARS-CoV-2 as a pandemic on March 11, 2020. We compared patients covered by Medicare or MedAdvantage plans to patients with any other non-Medicare insurance coverage (Figure1). 25% of our Medicare OPAT patients received antibiotics through home infusion compared to 60% of those with other insurance. We acknowledge that administering IV antibiotics at home would not have been appropriate for all of these patients, but the disparity between these groups represents a significant and avoidable harm to the Medicare population.

The discrepancy between Medicare and other insurers for coverage of antibiotics by home infusion has long been a frustration for ID providers and patients.11 The COVID-19 pandemic illustrates that it is
imperative that we advocate for our most vulnerable Americans by urging policy makers to revise CMS reimbursement schedules now. We recommend that CMS urgently adapt their current policies to offer reimbursement for Medicare patients to receive intravenous antibiotics via home infusion. Not only does home infusion of antibiotics reduce unnecessary healthcare exposure for high-risk patients during the COVID-19 pandemic, it results in cost savings to our healthcare system and patients.
**Funding:** This work is unfunded

**Conflict of Interest:** Amber Streifel, No conflict; Monica Sikka, No conflict
References

1. Norris AH, Shrestha NK, Allison GM, et al. 2018 IDSA Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019; 68(1): e1-e35.

2. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. DOI: 10.1056/NEJMo2008457.

3. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a Long-Term Care Facility – King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. ePub: 18 March 2020.

4. Yourish K, Lai K.K R, Ivory D, Smith M. One-Third of All U.S Coronavirus Deaths are Nursing Home Residents or Workers. New York Times. Available at: https://www.nytimes.com/interactive/2020/05/09/us/coronavirus-cases-nursing-homes-us.html Accessed: 15 May 2020

5. Severe Outcomes among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12- March 16, 2020. MMWR Morb Mortal Wkly Rep. ePub: 18 Mar 2020
6. Wolter JM, Cagney RA, McCormack JG. A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases. J Infect 2004; 48:263–8.

7. Polinski JM, Kowal MK, Gagnon M, Brennan TA, Shrank WH. Home infusion: safe, clinically effective, patient preferred, and cost saving. Healthcare, 5 (2017), pp. 68-80.

8. Reimbursement. Nhia.org. Available at: https://www.nhia.org/reimbursement/. Accessed 15 May 2020.

9. Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 Vaccine Development Landscape. Nat Rev Drug Discov 2020 May 19(5):305-6.

10. Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV2 as Compared with SARS-CoV1. N Engl J Med March 17, 2020.

11. Keller S, Pronovost P, Cosgrove S. What Medicare is Missing. Clin Infect Dis 2015; 61(12):1890-91.
Figure 1. Medicare vs Non-Medicare Insured Patient OPAT Setting Prior to COVID-19 Pandemic; October 1, 2019 through December 31, 2019
Figure 1